TY - JOUR
T1 - Targeting CLL-1 for acute myeloid leukemia therapy
AU - Ma, Hongbing
AU - Padmanabhan, Iyer Swaminathan
AU - Parmar, Simrit
AU - Gong, Yuping
N1 - Funding Information:
The first author was supported by the China Scholarship Council for 1 year’s study at MD Anderson Cancer center.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/4/24
Y1 - 2019/4/24
N2 - Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the past few years, an increasing number of targets such as CD33, CD123, CLL-1, CD47, CD70, and TIM3, have been developed for immunotherapy of AML. Among them, CLL-1 has attracted the researchers' attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 is an ideal target for AML. In this paper, we will review the expression of CLL-1 on normal cells and AML, the value of CLL-1 in diagnosis and follow-up, and targeting CLL-1 therapy-based antibody and chimeric antigen receptor T cell therapy as well as providing an overview of CLL-1 as a target for AML.
AB - Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the past few years, an increasing number of targets such as CD33, CD123, CLL-1, CD47, CD70, and TIM3, have been developed for immunotherapy of AML. Among them, CLL-1 has attracted the researchers' attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 is an ideal target for AML. In this paper, we will review the expression of CLL-1 on normal cells and AML, the value of CLL-1 in diagnosis and follow-up, and targeting CLL-1 therapy-based antibody and chimeric antigen receptor T cell therapy as well as providing an overview of CLL-1 as a target for AML.
KW - Acute myeloid leukemia
KW - CD371
KW - CLEC12A
KW - CLL-1
KW - DCAL-2
KW - hMICL
UR - http://www.scopus.com/inward/record.url?scp=85064823129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064823129&partnerID=8YFLogxK
U2 - 10.1186/s13045-019-0726-5
DO - 10.1186/s13045-019-0726-5
M3 - Review article
C2 - 31014360
AN - SCOPUS:85064823129
SN - 1756-8722
VL - 12
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 41
ER -